Lenalidomide and Eltrombopag for Treatment of Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

Scientists tested if Eltrombopag (ELT)would reduce the incidence of thrombocytopenia in myelodysplastic syndrome (MDS) by conducting a phase II multicenter trial of ELT and lenalidomide in adult patients with low or intermediate-1-risk MDS with symptomatic or transfusion-dependent anemia or thrombocytopenia.